<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "eribulin inj VIAL">
<dose><value>1.4</value>
<value>1.1</value>
<value>0.7</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>0.5 mg/mL</value>
</strength>
<frequency><value>WEEKLY</value>
</frequency>
<instruction><value>For 2 doses (DAYS 1 &amp; 8 of 21 day cycle). Administer dose by direct injection over 2 to 5 minutes.  </value>
</instruction>
<volume><value>2 mL</value>
</volume>
<units><value>mg/m2</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>If ANC is less than 1 X 109/L or Platelets are less than 75 X 109/L: Delay eribulin and contact prescriber. Dosage reduction recommended for hepatic dysfinction: Mild (Child-Pugh A): reduce dose to 1.1 mg/m2, Moderate (Child-Pugh B): reduce dose to 0.7 mg/m2. Dosage reduction recommended for renal dysfunction: CrCl of 30 to 50 mL/minute: reduce dose to 1.1 mg/m2. No data available for CrCl less than 30 mL/minute.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6123</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>